Abel KM, Drake R, Goldstein JM (2010) Sex differences in schizophrenia. Int Rev Psychiatry 22(5):417–428

PubMed  Google Scholar 

Abou Kassm S, Hoertel N, Naja W et al (2019) Metabolic syndrome among older adults with schizophrenia spectrum disorder: prevalence and associated factors in a multicenter study. Psychiatry Res 275:238–246

PubMed  Google Scholar 

Al-Salameh A, El Bouzegaoui N, Saraval-Gross M (2023) Diabetes and cardiovascular risk according to sex: an overview of epidemiological data from the early framingham reports to the cardiovascular outcomes trials. Ann Endocrinol (Paris) 84(1):57–68

PubMed  Google Scholar 

Andreassen Ole A, Djurovic S, Thompson Wesley K et al (2013) Improved detection of common variants associated with schizophrenia by leveraging pleiotropy with cardiovascular-disease risk factors. Am J Human Genetics 92(2):197–209

CAS  Google Scholar 

Andreou D, Saetre P, Fors BM et al (2020) Cardiac left ventricular ejection fraction in men and women with schizophrenia on long-term antipsychotic treatment. Schizophr Res 218:226–232

PubMed  Google Scholar 

Borelli CM, Solari H (2019) Schizophrenia. JAMA 322(13):1322

PubMed  Google Scholar 

Canuso CM, Pandina G (2007) Gender and schizophrenia. Psychopharmacol Bull 40(4):178–190

PubMed  Google Scholar 

Charlson FJ, Ferrari AJ, Santomauro DF et al (2018) Global epidemiology and burden of schizophrenia: findings from the global burden of disease study 2016. Schizophr Bull 44(6):1195–1203

PubMed  PubMed Central  Google Scholar 

Chen LJ, Hao JC, Ku PW et al (2018) Prospective associations of physical fitness and cognitive performance among inpatients with Schizophrenia. Psychiatry Res 270:738–743

CAS  PubMed  Google Scholar 

Correll CU, Solmi M, Veronese N et al (2017) Prevalence, incidence and mortality from cardiovascular disease in patients with pooled and specific severe mental illness: a large-scale meta-analysis of 3,211,768 patients and 113,383,368 controls. World Psychiatry 16(2):163–180

PubMed  PubMed Central  Google Scholar 

D’Agostino RB, Vasan RS, Pencina MJ et al (2008) General cardiovascular risk profile for use in primary care: the Framingham heart study. Circulation 117(6):743–53

PubMed  Google Scholar 

Daumit GL, Goff DC, Meyer JM et al (2008) Antipsychotic effects on estimated 10-year coronary heart disease risk in the CATIE schizophrenia study. Schizophr Res 105(1–3):175–187

PubMed  PubMed Central  Google Scholar 

De Hert M, Detraux J, Vancampfort D (2018) The intriguing relationship between coronary heart disease and mental disorders. Dialogues Clin Neurosci 20(1):31–40

PubMed  PubMed Central  Google Scholar 

Dehelean L, Marinescu I, Stovicek PO et al (2019) Cardiovascular anomalies and evolutionary risk factors in schizophrenia—multifactorial approach. Rom J Morphol Embryol 60(4):1105–1113

PubMed  Google Scholar 

Ellason JW, Ross CA (1995) Positive and negative symptoms in dissociative identity disorder and schizophrenia: a comparative analysis. J Nerv Ment Dis 183(4):236–241

CAS  PubMed  Google Scholar 

Foguet-Boreu Q, Guàrdia Sancho A, Santos Lopez JM et al (2020) Association between cognitive impairment and cardiovascular burden in patients with severe mental disorder. Cogn Neuropsychiatry 25(1):1–13

PubMed  Google Scholar 

Gabilondo A, Alonso-Moran E, Nuño-Solinis R et al (2017) Comorbidities with chronic physical conditions and gender profiles of illness in schizophrenia. Results from PREST, a new health dataset. J Psychosomatic Res 93:102–9

Google Scholar 

Galdas PM, Cheater F, Marshall P (2005) Men and health help-seeking behaviour: literature review. J Adv Nurs 49(6):616–623

PubMed  Google Scholar 

Goff DC, Sullivan LM, McEvoy JP et al (2005) A comparison of ten-year cardiac risk estimates in schizophrenia patients from the CATIE study and matched controls. Schizophr Res 80(1):45–53

PubMed  Google Scholar 

Hagi K, Nosaka T, Dickinson D et al (2021) Association between cardiovascular risk factors and cognitive impairment in people with Schizophrenia. JAMA Psychiatry 78(5):510–8

PubMed  Google Scholar 

Hjorthøj C, Stürup AE, McGrath JJ et al (2017) Years of potential life lost and life expectancy in schizophrenia: a systematic review and meta-analysis. Lancet Psychiatry 4(4):295–301

PubMed  Google Scholar 

Iadecola C, Parikh NS (2020) Framingham general cardiovascular risk score and cognitive impairment. J Am Coll Cardiol 75(20):2535–2537

PubMed  PubMed Central  Google Scholar 

Iadecola C, Duering M, Hachinski V et al (2019) Vascular cognitive impairment and dementia: JACC scientific expert panel. J Am Coll Cardiol 73(25):3326–3344

PubMed  PubMed Central  Google Scholar 

Janney CA, Ganguli R, Tang G et al (2015) Physical activity and sedentary behavior measured objectively and subjectively in overweight and obese adults with schizophrenia or schizoaffective disorders. J Clin Psychiatry 76(10):e1277–e1284

PubMed  Google Scholar 

Jauhar S, Johnstone M, McKenna PJ (2022) Schizophrenia. Lancet 399(10323):473–486

CAS  PubMed  Google Scholar 

Jin H, Folsom D, Sasaki A et al (2011) Increased Framingham 10-year risk of coronary heart disease in middle-aged and older patients with psychotic symptoms. Schizophr Res 125(2–3):295–299

PubMed  Google Scholar 

Kannel WB, McGee D, Gordon T (1976) A general cardiovascular risk profile: the framingham study. Am J Cardiol 38(1):46–51

CAS  PubMed  Google Scholar 

Kraal AZ, Moll AC, Arvanitis NR et al (2019) Metabolic syndrome is negatively associated with cognition among endothelial nitric oxide synthase (eNOS)-786C carriers in schizophrenia-spectrum disorders. J Psychiatr Res 117:142–147

PubMed  PubMed Central  Google Scholar 

Lancon C, Dassa D, Fernandez J et al (2012) Are cardiovascular risk factors associated with Verbal learning and memory impairment in patients with schizophrenia? A cross-sectional study. Cardiovasc Psychiatry Neurol 2012:1–8

Google Scholar 

Laursen TM, Munk-Olsen T, Vestergaard M (2012) Life expectancy and cardiovascular mortality in persons with schizophrenia. Curr Opin Psychiatry 25(2):83–88

PubMed  Google Scholar 

Li Z, Cui D, Xing M et al (2022) Differing prevalence and correlates of metabolic syndromes between chlorpromazine and clozapine: a 10-year retrospective study of a male chinese cohort. Curr Neuropharmacol 20(10):1969–1977

PubMed  PubMed Central  Google Scholar 

Lu C, Jin X, Liu N, et al (2024) The relationship of cardiovascular disease risk, clozapine antipsychotic use and cognitive function in a large Chinese schizophrenia cohort [J]. Brain Res 1845:149220

McCreadie RG (2003) Diet, smoking and cardiovascular risk in people with schizophrenia: descriptive study. Br J Psychiatry 183:534–539

CAS  PubMed  Google Scholar 

Mhalla A, Bel Hadj SW, Mensi R et al (2018) Lipid profile in schizophrenia: case control study. Tunis Med 96(1):22–9

PubMed  Google Scholar 

North BJ, Sinclair DA (2012) The intersection between aging and cardiovascular disease. Circ Res 110(8):1097–1108

CAS  PubMed  PubMed Central  Google Scholar 

Olfson M, Gerhard T, Huang C et al (2015) Premature mortality among adults with schizophrenia in the United States. JAMA Psychiat 72(12):1172–1181

Google Scholar 

Ratliff JC, Palmese LB, Reutenauer EL et al (2013) Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics 54(1):67–73

PubMed  Google Scholar 

Raudeberg R, Karr JE, Iverson GL et al (2023) Examining the repeatable battery for the assessment of neuropsychological status validity indices in people with schizophrenia spectrum disorders. Clin Neuropsychol 37(1):101–118

PubMed  Google Scholar 

Ringen PA, Engh JA, Birkenaes AB et al (2014) Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions. Front Psychiatry 5:137

PubMed  PubMed Central  Google Scholar 

Rossom RC, Hooker SA, O’Connor PJ et al (2022) Cardiovascular risk for patients with and without schizophrenia, schizoaffective disorder, or bipolar disorder. J Am Heart Assoc 11(6):21444

Google Scholar 

Rotella F, Cassioli E, Calderani E et al (2020) Long-term metabolic and cardiovascular effects of antipsychotic drugs. A meta-analysis of randomized controlled trials. Eur Neuropsychopharmacol 32:56–65

CAS  PubMed  Google Scholar 

Saharinen P, Eklund L, Alitalo K (2017) Therapeutic targeting of the angiopoietin-TIE pathway. Nat Rev Drug Discov 16(9):635–661

CAS  PubMed  Google Scholar 

Schneider JA, Arvanitakis Z, Bang W et al (2007) Mixed brain pathologies account for most dementia cases in community-dwelling older persons. Neurology 69(24):2197–2204

PubMed  Google Scholar 

Storch Jakobsen A, Speyer H, Nørgaard HCB et al (2018) Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders—Baseline and two-years findings from the CHANGE trial. Schizophr Res 199:96–102

PubMed  Google Scholar 

Storch Jakobsen A, Speyer H, Nørgaard HCB et al (2018) Associations between clinical and psychosocial factors and metabolic and cardiovascular risk factors in overweight patients with schizophrenia spectrum disorders—Baseline and two-years findings from the CHANGE trial. Schizophr Res 199:96–102